Galaxy Z Fold8 Sales Up 45%: How Apple’s iPhone Duo Unveil Sparked A Samsung Boom - Yahoo Finance

Today marks the official start of shipping for the iPhone Duo, but unless you pre-ordered one, you will have to wait a while for a unit to become available. While you wait, you can have a look at what Samsung has to offer. The Samsung Galaxy Z Fold8 is the only other wide foldable in the US market. Motorola allegedly has something in the works, but it will be months before we see it. Google has never been fast at launching new models, so we don’t expect a wide Pixel anytime soon.

Back in September, Samsung said that combined sales of the Galaxy Z Fold8 and Galaxy Z Fold8 Ultra in Europe were 50% higher than those of the Galaxy Z Fold7 last year. Today, the company is back with an update that covers the first nine weeks of availability. These are the best offers from our affiliate partners. We may get a commission from qualifying sales.

Johnny Hilbrant Partridge never worked an hour on Wall Street, but you’d never guess that by looking at him. Nearly every day, Partridge takes to YouTube to channel his inner finance bro as P. E. Guy, a puffer-vested private equity putz who brags about his million-dollar deals, Aspen manse and private plane. Partridge, who once taught fitness classes in Boston, debuted the character on social media last year, which boosted his following beyond Barry’s and SoulCycle devotees. Today, he has 400,000-plus Instagram followers, up from 7,000 about 18 months ago.

News|Articles|October 24, 2026 Baseline and on-treatment circulating tumor DNA (ctDNA) features, including TP53 mutations and methylation-based tumor fraction, were associated with early progression or prolonged progression-free survival (PFS) with first-line lorlatinib (Lorbrena) in patients with ALK-positive advanced non–small cell lung cancer (NSCLC), in exploratory analyses of the phase 3 CROWN trial (NCT03052608) presented at the 2026 European Society for Medical Oncology (ESMO) Congress.1Compared with long-term responders, who were progression free at 84 months (n = 30), early progressors, who had a PFS event within 12 months (n = 22), had a higher median number of altered genes at baseline (10 vs 6), a higher median blood-based tumor mutation burden (7.7 vs 5.1), and more frequent TP53 mutations (50% vs 17%). In the lorlatinib arm, the 7-year PFS rate was 65.0% (95% CI, 54.5%-77.4%) in patients with TP53 wild-type disease (n = 73) vs 40.8% (95% CI, 27.3%-61.1%) in those with TP53-mutated disease (n = 43; HR, 0.48; 95% CI, 0.268-0.857); median PFS was not reached (NR) vs 51.6 months (95% CI, 16.4-NR), respectively.

CML treatment has transformed long-term survival, allowing many patients receiving effective TKI therapy to achieve a life expectancy approaching that of the general population. Molecular response milestones guide personalized treatment decisions, helping clinicians assess treatment effectiveness, recognize inadequate responses, and adjust therapy when necessary.